



Company Contact – Jim Dorsey
BioClinica, Inc.
267-757-3040

Investor Contact – Linda Decker
Financial Media – Bill Gordon
Porter, LeVay & Rose, Inc.
212-564-4700

Trade Media – Beth Nestlerode
**Diccicco Battista
Communications**
484-342-3600

FOR IMMEDIATE RELEASE

**BIOCLINICA INKS MULTI-YEAR OUTSOURCING DEAL WITH LEADING
BIOPHARMACEUTICAL COMPANY**

**-- Company will Standardize Electronic Data Capture and Global Data Management for Frazer,
Pennsylvania-based Cephalon, Inc. --**

NEWTOWN, PA, February 4, 2010 – BioClinica, Inc., (NASDAQ: BIOC) a leading global provider of clinical trial services, has signed a three-year, multi-million dollar deal with Cephalon, Inc. for clinical trial technology and support services. As part of the Service Agreement, US-based data management staff at Cephalon will be hired by BioClinica to support clinical efforts of Cephalon.

BioClinica will provide end-to-end clinical data management services to Cephalon global clinical trial operations. Specific tasks include data management planning, clinical study set-up for electronic data capture (EDC), medical coding, adverse event reconciliation, clinical data management, and training for the clinical sites and investigators. The deal also expands plans by Cephalon to use BioClinica's Express™ electronic data capture (EDC) product as the default data capture system across clinical trial phases, from Phases I through IV. BioClinica will work with other functional service providers selected as part of Cephalon's initiative to optimize operational efficiency. BioClinica said it will see its role with Cephalon extended from one of a technology provider to that of a "key services partner".

Mark Weinstein, President and CEO of BioClinica said: "We will help Cephalon centralize and streamline its clinical data management operations through improved process standardization, consistency of delivery, economies of scale and cost savings. There are other technology players out there and certainly no shortage of service-based CROs, but BioClinica is the only organization that successfully blends those models into a true eClinical suite." The two firms have worked together since 2003 when Cephalon began using Phoenix Data Systems for electronic data capture. Phoenix Data Systems is now the core of BioClinica's eClinical division.

"Our long-standing relationship with BioClinica supported our analysis that they were the best partner to deliver clinical data management services for us. The agreement was cemented on the shared philosophy that technology-smart people are key for the optimization of our global clinical development process," said Dr. Charles Morris, Vice President of Worldwide Clinical Research at Cephalon.

-more-

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. Cephalon currently employs approximately 3,000 people in the United States and Europe.

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

#####